.svg)
We Don’t Bet on Science Experiments — We Build Pharma’s Next Blockbusters
Venture-built. Human-proven.
Ready for pharma deals from day one.
A New Playbook for Biotech Venture Building
Pharma is facing a $1.5T acquisition gap. But innovation has stalled—not due to science, but structure. Negev Labs is rewriting the model: we rapidly advance de-risked drug candidates with human data, structuring each for accelerated licensing or acquisition.
A New Frontier in Neuropsychiatry
Neuroplastogens represent a next-generation class of therapies with the potential to address major unmet needs in depression, apathy, neurodegeneration, and beyond. The pharma industry is primed for disruption — and we’re positioned to lead it.
Addressing large, underserved markets with strong pharma demand and limited innovation.
Lean studies designed to show early efficacy with less capital and shorter timelines.
Non-hallucinogenic drugs built for broad adoption and regulatory simplicity.
Repeatable. Scalable. Already Underway.
Our venture studio model is advancing promising development programs across neuropsychiatry - each supported by human data and built for pharma partnership.
With one company launched and the next company on deck, we are in execution mode.
Insider access to overlooked, high-potential biotech assets.
Every asset is backed by human data, dramatically reducing development risk.
Clear, focused development paths allow faster routes to pharma deals.
No long shots. Every drug is selected for licensing potential.
.png)
.png)
.png)
.svg)
%201.svg){kind=icon}
.svg)
